Cogent Biosciences (COGT) News Today $9.08 +0.02 (+0.22%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 Earnings Forecast for COGT Issued By Leerink PartnrsNovember 20 at 2:25 AM | americanbankingnews.comFY2024 EPS Forecast for Cogent Biosciences Lifted by AnalystCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technoNovember 18 at 2:30 AM | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for COGT EarningsNovember 17, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for COGT FY2024 EarningsNovember 17, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Trading Down 7% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Trading Down 7% - Time to Sell?November 15, 2024 | marketbeat.comEquities Analysts Set Expectations for COGT FY2027 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for Cogent Biosciences in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technology company will eNovember 15, 2024 | marketbeat.comWhat is Lifesci Capital's Estimate for COGT FY2024 Earnings?Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Lifesci Capital cut their FY2024 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky now anticipates that the technology company wilNovember 15, 2024 | marketbeat.comWedbush Reduces Earnings Estimates for Cogent BiosciencesCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Wedbush decreased their FY2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the technology company wiNovember 15, 2024 | marketbeat.comCogent Biosciences: Promising Clinical Developments and Strategic Milestones Warrant a Buy RecommendationNovember 14, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Issues Earnings ResultsCogent Biosciences (NASDAQ:COGT - Get Free Report) issued its quarterly earnings results on Tuesday. The technology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period in the prior year, the firm earned ($0.64) EPS.November 13, 2024 | marketbeat.comNeedham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00Needham & Company LLC lowered their target price on Cogent Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday.November 13, 2024 | marketbeat.comCogent Biosciences Reports Progress in Clinical Trials and Financial StandingNovember 13, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Amid Unjustified Stock DeclineNovember 6, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.3% - What's Next?Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3% - Time to Sell?November 5, 2024 | marketbeat.comCogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingNovember 5, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Cogent Biosciences (NASDAQ:COGT)HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Cogent Biosciences in a report on Monday.November 4, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from BrokeragesCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buyOctober 31, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Increases Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Hennion & Walsh Asset Management Inc. grew its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,9October 26, 2024 | marketbeat.comCogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy RatingOctober 25, 2024 | markets.businessinsider.comNeedham & Company LLC Reiterates Buy Rating for Cogent Biosciences (NASDAQ:COGT)Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Cogent Biosciences in a research report on Thursday.October 24, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Sets New 52-Week High - Here's What HappenedCogent Biosciences (NASDAQ:COGT) Hits New 52-Week High - What's Next?October 22, 2024 | marketbeat.comHere's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn SituationOctober 21, 2024 | finance.yahoo.comCogent Biosciences (NASDAQ:COGT) Trading Down 2.4% - Here's WhyCogent Biosciences (NASDAQ:COGT) Trading Down 2.4% - Should You Sell?October 16, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 4.6% - Time to Buy?Cogent Biosciences (NASDAQ:COGT) Trading Up 4.6% - Still a Buy?October 10, 2024 | marketbeat.comAnalysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 TargetOctober 10, 2024 | msn.comDimensional Fund Advisors LP Sells 463,901 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Dimensional Fund Advisors LP trimmed its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 33.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 930,297 shares of the technology company's stock after selling 463,901 shares during the period.October 8, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given aOctober 6, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Algert Global LLCAlgert Global LLC lowered its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 56.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,034 shares of the technology company's stock after selling 20October 4, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Down 4.2% Cogent Biosciences (NASDAQ:COGT) Shares Down 4.2%October 1, 2024 | marketbeat.comPoint72 Asset Management L.P. Increases Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Point72 Asset Management L.P. increased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 56.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,470,398 shares of the technSeptember 30, 2024 | marketbeat.comProfund Advisors LLC Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Profund Advisors LLC reduced its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 68.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,494 shares of the technoloSeptember 28, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Grows Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Deerfield Management Company L.P. Series C increased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 144.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,744,263 shares of the technology company'sSeptember 26, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Stake in Cogent Biosciences, Inc. (NASDAQ:COGT)Point72 Asset Management L.P. lifted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 124.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 14,986,398 shares of the technology company's stock after purchasing an additionaSeptember 25, 2024 | marketbeat.comCitigroup Raises Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00Citigroup raised their price target on shares of Cogent Biosciences from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday.September 24, 2024 | marketbeat.comSofinnova Investments Inc. Purchases 372,515 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Sofinnova Investments Inc. lifted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,773,286 shares of the technologySeptember 17, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 3.3%Cogent Biosciences (NASDAQ:COGT) Trading Down 3.3%September 12, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from AnalystsCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation tSeptember 11, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Up 5.8%Cogent Biosciences (NASDAQ:COGT) Shares Up 5.8%September 9, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 6.6%Cogent Biosciences (NASDAQ:COGT) Trading Down 6.6%September 6, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Expected to Earn FY2027 Earnings of ($1.10) Per ShareCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at Wedbush boosted their FY2027 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Tuesday, September 3rd. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earniSeptember 6, 2024 | marketbeat.comRobert W. Baird Increases Cogent Biosciences (NASDAQ:COGT) Price Target to $10.00Robert W. Baird boosted their price objective on shares of Cogent Biosciences from $8.00 to $10.00 and gave the company a "neutral" rating in a research report on Thursday.September 5, 2024 | marketbeat.comHC Wainwright Equities Analysts Lift Earnings Estimates for Cogent Biosciences, Inc. (NASDAQ:COGT)Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, September 3rd. HC Wainwright analyst R. Burns now antSeptember 5, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Rating Reiterated by WedbushWedbush reaffirmed a "neutral" rating and issued a $11.00 target price (up from $10.00) on shares of Cogent Biosciences in a report on Tuesday.September 3, 2024 | marketbeat.comPositive Outlook for Cogent Biosciences Backed by Clinical Trial Progress and Efficient ManagementSeptember 3, 2024 | markets.businessinsider.comHC Wainwright Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $17.00HC Wainwright cut their target price on shares of Cogent Biosciences from $19.00 to $17.00 and set a "buy" rating for the company in a report on Tuesday.September 3, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Panagora Asset Management Inc.Panagora Asset Management Inc. reduced its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 19.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 246,333 shares of the technology company's stock after selling 60,912 shares dAugust 31, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Up 4.3%Cogent Biosciences (NASDAQ:COGT) Trading 4.3% HigherAugust 30, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Makes New $1.08 Million Investment in Cogent Biosciences, Inc. (NASDAQ:COGT)Hennion & Walsh Asset Management Inc. acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 127,712 shares of the techAugust 20, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading 10.1% Higher Cogent Biosciences (NASDAQ:COGT) Stock Price Up 10.1%August 16, 2024 | marketbeat.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play. COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼0.340.46▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼223▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enlivex Therapeutics News Organon & Co. News ImmunityBio News Immunovant News Rhythm Pharmaceuticals News Apellis Pharmaceuticals News MoonLake Immunotherapeutics News Agios Pharmaceuticals News Verona Pharma News PTC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
